secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2022-04-20T23:59:59+00:00
Accession:  0001193805-22-000672
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus ARCT-154 Phase 3 shows 55% efficacy vs COVID-19, 95% vs severe disease
-------------------------------------------------------------------------------

- Two 5-mcg doses of ARCT-154 provided 55% efficacy (95% CI 46.9-61.9) against symptomatic COVID-19.
- Vaccine demonstrated 95.3% efficacy (95% CI 80.4-98.9) against severe COVID-19 including deaths.
- No cases of myocarditis or pericarditis reported; unsolicited adverse events comparable to placebo.
- Data submitted to Vietnam Ministry of Health for EUA; ARCT-154 advancing to pivotal booster trial in major markets.
- Also amended loan with Western Alliance Bank to extend interest-only payments to Aug 1, 2022, and terminated Israeli supply deal for first-gen vaccine (no penalty).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522000672/0001193805-22-000672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522000672/e621578_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-22-000672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer